Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 1, 2019Clinical Pharmacology & TherapeuticsOpen Access

Population Pharmacokinetic Modeling and Exposure–Response Assessment for the Antibody‐Drug Conjugate Brentuximab Vedotin in Hodgkin's Lymphoma in the Phase III ECHELON‐1 Study

View Full Paper
Ask AI
Bookmark
Share

Authors

ASAjit SuriTakeda (United States)DMDiane R. MouldPhoenixville HospitalGSGregory Chi SongKunming Medical University

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Suri et al. (2019) studied this question.

synapsesocial.com/papers/6a3447fe889c90a2f3a74ce8https://doi.org/10.1002/cpt.1530
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Population PK and Exposure–Response Relationships for the Antibody–Drug Conjugate Brentuximab Vedotin in CTCL Patients in the Phase III ALCANZA Study2018 · 34 citations
  2. 2Toward Greater Insights on Pharmacokinetics and Exposure–Response Relationships for Therapeutic Biologics in Oncology Drug Development2017 · 51 citations
  3. 3Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas2010 · 1,373 citations
  4. 4Human serum albumin homeostasis: a new look at the roles of synthesis, catabolism, renal and gastrointestinal excretion, and the clinical value of serum albumin measurements2016 · 791 citations
  5. 5Optimizing Oncology Therapeutics Through Quantitative Translational and Clinical Pharmacology: Challenges and Opportunities2014 · 97 citations